HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Case of fulminant type 1 diabetes induced by the anti-programmed death-ligand 1 antibody, avelumab

This item is licensed under: Creative Commons Attribution-NonCommercial 4.0 International

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:https://doi.org/10.1111/jdi.13022


Title: Case of fulminant type 1 diabetes induced by the anti-programmed death-ligand 1 antibody, avelumab
Authors: Shibayama, Yui Browse this author
Kameda, Hiraku Browse this author
Ota, Shoichiro Browse this author
Tsuchida, Kazuhisa Browse this author
Cho, Kyu Yong Browse this author
Nakamura, Akinobu Browse this author →KAKEN DB
Miyoshi, Hideaki Browse this author →KAKEN DB
Atsumi, Tatsuya Browse this author →KAKEN DB
Keywords: Anti-programmed death-ligand 1 antibody
Fulminant type 1 diabetes
Immune-related adverse events
Issue Date: Sep-2019
Publisher: John Wiley & Sons
Journal Title: Journal of diabetes investigation
Volume: 10
Issue: 5
Start Page: 1385
End Page: 1387
Publisher DOI: 10.1111/jdi.13022
Abstract: With the expansive use of immune checkpoint inhibitors, the frequency of immune-related adverse events, including autoimmune type 1 diabetes, has been exponentially increased. The anti-programmed death-ligand 1 antibody, avelumab, has recently been approved for metastatic Merkel cell carcinoma therapy. Here, we report a patient that developed fulminant type 1 diabetes during avelumab treatment. An 81-year-old woman with no history of diabetes received avelumab for metastatic Merkel cell carcinoma. Elevated plasma glucose level (483 mg/dL), hemoglobin A1c level (7.5%) and ketosis were observed after 10 courses of avelumab without any symptoms related to hyperglycemia. As the laboratory tests showed insulin depletion, we diagnosed her with fulminant type 1 diabetes induced by avelumab. This is the first reported case of avelumab-induced type 1 diabetes, illustrating the necessity for close monitoring of glycemic control during avelumab therapy, as well as other immune checkpoint inhibitors.
Rights: https://creativecommons.org/licenses/by-nc/4.0/
Type: article
URI: http://hdl.handle.net/2115/75841
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

Feedback - Hokkaido University